<!DOCTYPE html>
<html lang="en">
<head>
<script async src="https://www.googletagmanager.com/gtag/js?id=G-6H85DH0R8S"></script>
<script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments)}gtag('js',new Date());gtag('config','G-6H85DH0R8S');</script>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>GLP-1 Weight Loss Results: What Clinical Trials Actually Show — glp1.md</title>
<meta name="description" content="Real weight loss data from STEP, SURMOUNT, and SELECT trials for semaglutide and tirzepatide. Average results, response rates, and what to expect.">
<link rel="canonical" href="https://glp1.md/blog/glp1-weight-loss-results.html">
<link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle' letter-spacing='-0.5'%3E.md%3C/text%3E%3C/svg%3E">
<link rel="preconnect" href="https://fonts.googleapis.com">
<link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
<style>
:root{--bg-primary:#fff;--bg-secondary:#f8fafc;--bg-tertiary:#f1f5f9;--text-primary:#0f172a;--text-secondary:#475569;--text-muted:#94a3b8;--accent:#0d9488;--accent-dark:#0f766e;--accent-light:#ccfbf1;--border:#e2e8f0;--font-display:'Source Serif 4',Georgia,serif;--font-body:'Inter',-apple-system,sans-serif}
*{margin:0;padding:0;box-sizing:border-box}
body{font-family:var(--font-body);background:var(--bg-primary);color:var(--text-primary);line-height:1.7;font-size:16px}
header{position:fixed;top:0;left:0;right:0;z-index:100;background:rgba(255,255,255,0.95);backdrop-filter:blur(10px);border-bottom:1px solid var(--border)}
.header-inner{max-width:1100px;margin:0 auto;padding:16px 24px;display:flex;justify-content:space-between;align-items:center}
.logo{font-family:var(--font-display);font-size:22px;font-weight:600;color:var(--text-primary);text-decoration:none}
.logo span{color:var(--accent)}
nav{display:flex;gap:32px}
nav a{color:var(--text-secondary);text-decoration:none;font-size:14px;font-weight:500;transition:color .2s}
nav a:hover{color:var(--accent)}
article{max-width:720px;margin:0 auto;padding:140px 24px 64px}
.breadcrumb{font-size:13px;color:var(--text-muted);margin-bottom:24px}
.breadcrumb a{color:var(--accent);text-decoration:none}
.article-meta{font-size:13px;color:var(--text-muted);margin-bottom:32px}
h1{font-family:var(--font-display);font-size:clamp(32px,4.5vw,42px);font-weight:700;line-height:1.2;margin-bottom:16px}
h2{font-family:var(--font-display);font-size:24px;font-weight:700;margin:40px 0 16px}
h3{font-family:var(--font-display);font-size:19px;font-weight:600;margin:28px 0 12px}
p{font-size:17px;color:var(--text-secondary);margin-bottom:20px}
ul,ol{margin:0 0 20px 24px;color:var(--text-secondary);line-height:1.8}
li{margin-bottom:8px}
.info-box{background:var(--bg-secondary);border:1px solid var(--border);border-left:4px solid var(--accent);border-radius:8px;padding:20px;margin:32px 0}
.info-box h3{margin-top:0;margin-bottom:8px}
.info-box p{font-size:14px;margin-bottom:0}
.warning-box{background:#fef2f2;border:1px solid #fecaca;border-left:4px solid #ef4444;border-radius:8px;padding:20px;margin:32px 0}
.warning-box h3{font-family:var(--font-display);font-size:17px;font-weight:600;margin-bottom:8px;color:#991b1b}
.warning-box p{font-size:14px;color:#7f1d1d;line-height:1.6;margin-bottom:0}
table{width:100%;border-collapse:collapse;margin:24px 0;border:1px solid var(--border);border-radius:8px;overflow:hidden}
thead{background:var(--bg-secondary)}
th{padding:12px 16px;text-align:left;font-size:13px;font-weight:600;border-bottom:1px solid var(--border)}
td{padding:12px 16px;font-size:14px;color:var(--text-secondary);border-bottom:1px solid var(--border)}
tr:last-child td{border-bottom:none}
tr:hover{background:var(--bg-secondary)}
.source-list{background:var(--bg-secondary);border:1px solid var(--border);border-radius:8px;padding:24px;margin:40px 0}
.source-list h3{margin-top:0}
.source-list ol{font-size:14px;color:var(--text-muted);margin-bottom:0}
.source-list a{color:var(--accent);text-decoration:none}
footer{background:var(--bg-secondary);border-top:1px solid var(--border);padding:48px 24px}
.footer-inner{max-width:1100px;margin:0 auto;display:grid;grid-template-columns:2fr 1fr 1fr 1fr;gap:40px}
.footer-brand p{font-size:14px;color:var(--text-muted);line-height:1.6}
.footer-links h4{font-size:12px;font-weight:600;color:var(--text-primary);text-transform:uppercase;letter-spacing:.5px;margin-bottom:12px}
.footer-links a{display:block;color:var(--text-muted);text-decoration:none;font-size:14px;margin-bottom:8px;transition:color .2s}
.footer-links a:hover{color:var(--accent)}
.footer-bottom{max-width:1100px;margin:32px auto 0;padding-top:24px;border-top:1px solid var(--border);display:flex;justify-content:space-between;font-size:13px;color:var(--text-muted)}
@media(max-width:768px){nav{display:none}.footer-inner{grid-template-columns:1fr;gap:24px}.footer-bottom{flex-direction:column;gap:12px;text-align:center}article{padding:100px 16px 40px}table{font-size:12px}th,td{padding:8px 10px}}
</style>
</head>
<body>
<header>
<div class="header-inner">
<a href="/" class="logo">glp1<span>.md</span></a>
<nav>
<a href="/comparison.html">Compare Meds</a>
<a href="/side-effects.html">Side Effects</a>
<a href="/cost-insurance.html">Cost & Insurance</a>
<a href="/eligibility.html">Who Qualifies</a>
<a href="/blog/">Articles</a>
</nav>
</div>
</header>

<article>
<div class="breadcrumb"><a href="/">Home</a> / <a href="/blog/">Articles</a> / GLP-1 Weight Loss Results</div>
<h1>GLP-1 Weight Loss Results: What the Clinical Trial Data Actually Shows</h1>
<div class="article-meta">Updated February 2026 · 9 min read</div>

<p>If you have spent any time reading about GLP-1 medications online, you have probably encountered a wide range of weight loss claims — from conservative estimates to breathless headlines. The reality, as documented in randomized controlled trials involving tens of thousands of participants, falls somewhere specific. Here is what the data actually says.</p>

<h2>The Headline Numbers</h2>

<p>The major clinical trial programs for GLP-1 and dual GIP/GLP-1 agonists have produced remarkably consistent results across different patient populations. The table below summarizes the primary weight loss outcomes from each landmark trial.</p>

<table>
<thead>
<tr><th>Trial</th><th>Drug (Dose)</th><th>Duration</th><th>Avg. Weight Loss</th><th>Placebo Loss</th></tr>
</thead>
<tbody>
<tr><td>STEP 1</td><td>Semaglutide 2.4 mg</td><td>68 weeks</td><td>-14.9%</td><td>-2.4%</td></tr>
<tr><td>STEP 2</td><td>Semaglutide 2.4 mg (T2D)</td><td>68 weeks</td><td>-9.6%</td><td>-3.4%</td></tr>
<tr><td>STEP 3</td><td>Semaglutide 2.4 mg + IBT</td><td>68 weeks</td><td>-16.0%</td><td>-5.7%</td></tr>
<tr><td>SURMOUNT-1</td><td>Tirzepatide 15 mg</td><td>72 weeks</td><td>-22.5%</td><td>-2.4%</td></tr>
<tr><td>SURMOUNT-2</td><td>Tirzepatide 15 mg (T2D)</td><td>72 weeks</td><td>-14.7%</td><td>-3.2%</td></tr>
<tr><td>SELECT</td><td>Semaglutide 2.4 mg</td><td>208 weeks</td><td>-9.4%</td><td>-0.9%</td></tr>
</tbody>
</table>
<p style="font-size:13px;color:var(--text-muted);">IBT = intensive behavioral therapy. T2D = patients with type 2 diabetes. All results represent intention-to-treat analysis.</p>

<p>Several things stand out in this data. First, weight loss is substantially greater in patients without type 2 diabetes. STEP 1 (no diabetes) showed 14.9 percent loss with semaglutide, while STEP 2 (with diabetes) showed 9.6 percent — a meaningful gap. The same pattern holds for tirzepatide: 22.5 percent in SURMOUNT-1 versus 14.7 percent in SURMOUNT-2. Insulin resistance appears to blunt the weight loss response, though the reasons are not fully understood.</p>

<p>Second, tirzepatide consistently outperforms semaglutide on weight loss. The SURMOUNT-1 result of 22.5 percent average body weight reduction at the highest dose is the largest ever recorded for a pharmaceutical intervention in a phase 3 trial. For a 220-pound person, that translates to roughly 50 pounds lost over 72 weeks.</p>

<h2>What "Average" Hides: The Distribution of Response</h2>

<p>Averages are useful but incomplete. In any trial, some patients lose substantially more weight than the mean, and some lose less. The distribution matters because it affects whether a given patient should expect the medication to work for them.</p>

<p>In STEP 1, approximately one-third of participants on semaglutide 2.4 mg lost more than 20 percent of their body weight. About 12 percent lost less than 5 percent. The rest fell somewhere in between. In SURMOUNT-1 with tirzepatide 15 mg, over 36 percent of participants lost more than 25 percent of their body weight, and roughly 63 percent lost at least 20 percent.</p>

<p>These response rates are worth dwelling on. In the tirzepatide trial, nearly two-thirds of participants hit the 20 percent threshold — a number that was previously associated mainly with surgical intervention. At the same time, a nontrivial minority (around 8 to 10 percent) had a minimal response. There is genuine variability in how individuals respond to these medications, and the biological reasons for that variability are an active area of research.</p>

<h2>The Time Course of Weight Loss</h2>

<p>Weight loss with GLP-1 agonists is not immediate. Both semaglutide and tirzepatide require gradual dose escalation over the first 16 to 20 weeks, and weight loss tracks closely with dose. In the STEP trials, participants typically saw modest weight loss during the titration phase, with the rate of loss accelerating once the maintenance dose was reached.</p>

<p>Peak weight loss in most trials occurred between weeks 60 and 72. After that point, weight tended to stabilize — the curve flattened rather than continuing to decline. This plateau is a normal physiological response. As body weight decreases, resting metabolic rate drops, and the body's energy expenditure adjusts to the new lower weight. The medication continues to suppress appetite, but the caloric deficit narrows.</p>

<p>In the SELECT trial, which followed patients for four years (208 weeks), the weight loss trajectory showed an initial steep decline, a plateau at around 60 to 80 weeks, and then a very gradual regain over the subsequent years — though participants remained well below their baseline weight throughout the study. Average weight loss at the end of the four-year period was 9.4 percent, compared to the 15 percent seen at the nadir. This long-term data is important because it suggests that some degree of weight regain may occur even while continuing the medication.</p>

<h2>What Happens When You Stop</h2>

<p>This is the question that comes up most often, and the data is clear: most of the weight comes back.</p>

<p>The STEP 1 extension study, published in Diabetes, Obesity and Metabolism in 2022, followed participants for one year after discontinuing semaglutide. Within 52 weeks of stopping the drug, participants regained approximately two-thirds of the weight they had lost. Cardiometabolic improvements — in blood pressure, lipids, and inflammatory markers — also reversed.</p>

<p>The SURMOUNT-4 trial showed a similar pattern with tirzepatide. After a 36-week lead-in period on the drug, participants who were switched to placebo regained about 14 percent of body weight over the subsequent 52 weeks, while those who continued on tirzepatide lost an additional 5.5 percent.</p>

<p>This should not be surprising. Obesity is a chronic condition driven by biological mechanisms that do not resolve when body weight decreases. The hormonal signals that promote weight regain — increased ghrelin, decreased leptin, reduced energy expenditure — reassert themselves when the pharmacological intervention is removed. This is not a failure of willpower. It is physiology.</p>

<p>The practical implication is that for most patients, GLP-1 medications are a long-term treatment, not a short course. This has significant cost implications, which we address in a <a href="/blog/glp1-insurance-coverage.html" style="color:var(--accent)">separate article on insurance and coverage</a>.</p>

<h2>Body Composition: Fat vs. Muscle</h2>

<p>One concern that has received substantial attention is whether the weight lost on GLP-1 medications is primarily fat or whether significant lean mass (muscle) is also lost. This matters because lean mass loss can reduce functional capacity and metabolic rate.</p>

<p>A substudy of STEP 1, using dual-energy X-ray absorptiometry (DEXA), found that approximately 39 percent of total weight lost was lean mass. This is roughly comparable to the lean mass percentage lost with caloric restriction alone and somewhat higher than what is typically seen after bariatric surgery (where lean mass accounts for about 25 to 30 percent of total weight lost).</p>

<p>A more recent analysis of tirzepatide, presented at the 2023 American Diabetes Association meeting, found a similar ratio. Whether resistance exercise can shift this proportion — preserving more lean mass while still losing fat — is an active question. Most clinical guidelines now recommend that patients on GLP-1 agonists incorporate strength training and adequate protein intake (generally 1.0 to 1.2 grams per kilogram of ideal body weight per day) to mitigate lean mass loss.</p>

<h2>Comparing to Other Weight Loss Approaches</h2>

<p>To put GLP-1 results in context, it helps to compare them against other interventions:</p>

<ul>
<li><strong>Lifestyle modification alone</strong> (diet + exercise counseling): Average weight loss of 3 to 5 percent of body weight at one year. Regain is common.</li>
<li><strong>Older weight loss medications</strong> (phentermine, orlistat): Average loss of 5 to 10 percent. Limited long-term data.</li>
<li><strong>Semaglutide 2.4 mg (Wegovy)</strong>: 15 percent average loss at 68 weeks.</li>
<li><strong>Tirzepatide 15 mg (Zepbound)</strong>: 22.5 percent average loss at 72 weeks.</li>
<li><strong>Roux-en-Y gastric bypass</strong>: 25 to 35 percent average loss, sustained over 5 to 10 years in most patients.</li>
<li><strong>Sleeve gastrectomy</strong>: 20 to 25 percent average loss at 5 years.</li>
</ul>

<p>The gap between tirzepatide and bariatric surgery has narrowed considerably. For patients who are not candidates for surgery — or who prefer a non-surgical approach — GLP-1 agonists now offer weight loss outcomes that were previously unattainable without an operation.</p>

<h2>What to Realistically Expect</h2>

<p>If you are starting a GLP-1 medication for weight loss, here is a reasonable set of expectations based on the trial data:</p>

<ul>
<li>During the first 4 to 8 weeks (dose titration), weight loss will be modest — perhaps 2 to 4 percent of body weight.</li>
<li>The steepest weight loss typically occurs between months 3 and 12 on the maintenance dose.</li>
<li>By 12 to 18 months, most patients reach a plateau. For semaglutide, that plateau is usually around 15 percent loss; for tirzepatide, around 20 to 22 percent.</li>
<li>About 10 percent of patients will have a minimal response (less than 5 percent loss). If you fall into this category after reaching the maximum dose for 3 to 6 months, discuss alternatives with your physician.</li>
<li>If you stop the medication, expect to regain a significant portion of the lost weight over the following 6 to 12 months.</li>
</ul>

<p>These are averages. Your results will depend on your baseline weight, metabolic health, diet, physical activity, and individual biology. But the overall trajectory is well established across multiple large trials, and there is no reason to expect it will look fundamentally different for a given patient than it does in the aggregate data.</p>

<div class="source-list">
<h3>Sources</h3>
<ol>
<li>Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. <em>N Engl J Med</em>. 2021;384(11):989-1002. (STEP 1)</li>
<li>Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). <em>Lancet</em>. 2021;397(10278):971-984.</li>
<li>Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy (STEP 3). <em>JAMA</em>. 2021;325(14):1403-1413.</li>
<li>Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. <em>N Engl J Med</em>. 2022;387(3):205-216. (SURMOUNT-1)</li>
<li>Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). <em>Lancet</em>. 2023;402(10402):613-626.</li>
<li>Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. <em>N Engl J Med</em>. 2023;389(24):2221-2232. (SELECT)</li>
<li>Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. <em>Diabetes Obes Metab</em>. 2022;24(8):1553-1564.</li>
<li>Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). <em>JAMA</em>. 2024;331(1):38-48.</li>
</ol>
</div>
</article>

<footer>
<div class="footer-inner">
<div class="footer-brand">
<a href="/" class="logo">glp1<span>.md</span></a>
<p>Part of the <a href="https://thrive.md" style="color:var(--accent);text-decoration:none">thrive.md</a> health network. Evidence-based medication information, reviewed by healthcare professionals.</p>
</div>
<div class="footer-links">
<h4>Medications</h4>
<a href="/comparison.html">Compare All</a>
<a href="https://ozempic.md">Ozempic</a>
<a href="https://wegovy.md">Wegovy</a>
<a href="https://mounjaro.md">Mounjaro</a>
</div>
<div class="footer-links">
<h4>Information</h4>
<a href="/side-effects.html">Side Effects</a>
<a href="/cost-insurance.html">Cost & Insurance</a>
<a href="/eligibility.html">Who Qualifies</a>
<a href="/blog/">Articles</a>
</div>
<div class="footer-links">
<h4>About</h4>
<a href="https://thrive.md/editorial-policy.html">Editorial Policy</a>
<a href="https://thrive.md/medical-review.html">Medical Review</a>
<a href="mailto:hello@thrive.md">Contact</a>
</div>
</div>
<div class="footer-bottom">
<p>&copy; 2026 glp1.md · A <a href="https://thrive.md" style="color:var(--text-muted);text-decoration:none">thrive.md</a> property</p>
<p><strong>Medical Disclaimer:</strong> This site provides information, not medical advice. Always consult your healthcare provider.</p>
</div>
</footer>
</body>
</html>